During the past decade, Centro de Investigaciones Medicas Mar Del Plata conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 11 clinical trials were completed, i.e. on average, 39.3% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 11 clinical trials were completed. i.e. 61.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Investigaciones Medicas Mar Del Plata" #1 sponsor was "Boehringer Ingelheim" with 5 trials, followed by "Janssen Research & Development, LLC" with 4 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "R-Pharm International, LLC" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Investigaciones Medicas Mar Del Plata" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Brigham and Women's Hospital" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Investigaciones Medicas Mar Del Plata" are "Rheumatoid Arthritis" (6 trials), "Colitis, Ulcerative" (3 trials), "Ulcerative Colitis" (3 trials), "Crohn's Disease" (2 trials) and "Eosinophilic Esophagitis" (2 trials). Many other conditions were trialed in "Centro de Investigaciones Medicas Mar Del Plata" in a lesser frequency.

Most popular intervention types in "Centro de Investigaciones Medicas Mar Del Plata" are "Drug" (29 trials), "Other" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Empagliflozin" (3 trials), "Adalimumab" (2 trials), "BI 685509" (2 trials) and "CC-93538" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Investigaciones Medicas Mar Del Plata" are 28 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Centro de Investigaciones Medicas Mar Del Plata". undefined are not yet recruiting, 13 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Centro de Investigaciones Medicas Mar Del Plata, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Investigaciones Medicas Mar Del Plata, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".